Equity Profile
Post-Earnings Recap
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.56 | $-0.78 | +37.36% |
| Revenue | N/A | $196M | N/A |
management commentary, guidance changes, and full analysis available with Pro.
Ionis Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative therapies for serious diseases....
EPS
Earnings per share is a key indicator of the company's profitability and financial health.
Revenue
Revenue figures help gauge the company's sales performance and market demand for its products.
Wall Street expectations, options signals, track record, and call prep available with Pro.
| EPS | $-0.56 | $-0.78 | +37.36% |
| Revenue | N/A | $196M | N/A |
Tone: Cautiously Optimistic
Management expressed satisfaction with the EPS results, highlighting a positive surprise. They emphasized their commitment to ongoing projects despite the lack of revenue data.
We are pleased with our EPS performance this quarter, exceeding expectations.
While we don't have revenue figures to report, we remain focused on our strategic initiatives.
Ionis Pharmaceuticals reported a narrower loss than analysts expected, which contributed to a slight increase in stock price. The positive EPS surprise indicates better-than-anticipated cost management or operational efficiency. However, the lack of revenue data leaves some uncertainty about the company's overall financial health moving forward.
EPS Beat Streak
1Q
EPS Beat Rate
88%
Avg EPS Surprise
+52.29%
Avg Stock Reaction
+1.02%
In the last quarter, Ionis reported an EPS of -$1.41, which was worse than analysts' expectations. The stock reacted negatively, dropping 5.29% the following day.
Management Promises & Guidance
Analysts expect Ionis to report a loss this quarter, with a consensus EPS of -$0.78 and revenue of $196 million. The market is closely watching for any signs of improvement in financial performance.
Bull Case
If Ionis can beat EPS estimates and show stronger revenue growth, it may indicate that its therapies are gaining traction, potentially boosting investor confidence.
Bear Case
Conversely, if the company misses expectations again, it could raise concerns about its product pipeline and ability to generate revenue, leading to further stock declines.
EPS
-$0.78Earnings per share is a key indicator of the company's profitability and financial health.
Revenue
$196MRevenue figures help gauge the company's sales performance and market demand for its products.
Expectations
The print will turn on these two things.
Q1
Will Ionis achieve an EPS of better than -$0.78?
This figure is critical as it directly impacts investor sentiment and confidence in the company's financial recovery.
Q2
What is the revenue outlook for the upcoming quarters?
Understanding revenue trends will provide insight into the demand for Ionis's therapies and its growth potential.
Edge
Why consensus could be wrong
The Street is underestimating the potential for Ionis to exceed its EPS estimates based on recent positive trends in its pipeline.
Supporting Evidence
Ionis has historically beaten EPS estimates 88% of the time, indicating a strong track record.
The options market is pricing a larger move than historical averages, suggesting heightened expectations for a surprise.
Insider selling may reflect a cautious sentiment, but it does not necessarily indicate a lack of confidence in upcoming results.
Key Risk
If Ionis reports an EPS better than -$0.42, it could challenge the current bearish sentiment.
Edge
Pre-commit to what would confirm each case.
The market is debating whether Ionis can turn around its financial performance after a series of mixed results.
Bull Confirmed If
An EPS of -$0.42 or better, along with revenue exceeding $235 million, would confirm a strong recovery narrative.
Bear Confirmed If
An EPS worse than -$0.96 and revenue below $159 million would confirm ongoing challenges for the company.
Pre-Earnings Positioning
Implied Move
±6.76%
Historical Avg
±2.9%
The options market is pricing in a significant move around the earnings report, suggesting that investors are anticipating volatility.
Options are pricing a 6.76% move, while the stock has averaged only 2.9% over the last 8 quarters, indicating a rich setup.
ATM IV
0.4%
30d HV
25.1%
Edge
Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.
Bought
$0.00
0 sh
0 insiders
Sold
$1.2M
16,494 sh
4 insiders
Net
$1.2M
Net selling
Most Active Insiders· 5 open-market trades
$381,366.52
Net selling
$418,952.64
Net selling
$368,488.24
Net selling
$73,015.87
Net selling
Recent Transactions
Apr 16, 2026 · @ $74.56
5,619 sh
$418,952.64
Apr 16, 2026 · @ $75.17
4,902 sh
$368,488.24
Open-market trades only (Form 4 codes P/S). Awards, exercises, and tax-withholding excluded as routine compensation noise.
Preparation
Likely market behavior by outcome — not investment advice.
Beat & Raise
If Ionis beats expectations, history suggests the stock could rise by an average of 0.86% the next day, confirming a positive trend.
In-Line / Cautious
If results are in line with expectations, the stock may see muted movement as investors await further guidance.
Miss
If Ionis misses expectations, history suggests a potential drop of about 5.29%, reflecting continued concerns about its performance.
Preparation
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
Polaris Inc.
Apr 15, 2026 · @ $76.19
4,466 sh
$340,264.54
Apr 16, 2026 · @ $75.04
973 sh
$73,015.87
Apr 15, 2026 · @ $76.97
534 sh
$41,101.98